Moore Capital Management LP Sells 20,000 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Moore Capital Management LP lessened its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 50.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,000 shares of the biotechnology company's stock after selling 20,000 shares during the period. Moore Capital Management LP's holdings in Ascendis Pharma A/S were worth $2,753,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ASND. Rice Hall James & Associates LLC boosted its stake in shares of Ascendis Pharma A/S by 2.0% in the 4th quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company's stock valued at $22,562,000 after purchasing an additional 3,274 shares in the last quarter. abrdn plc boosted its stake in shares of Ascendis Pharma A/S by 18.3% in the 4th quarter. abrdn plc now owns 187,180 shares of the biotechnology company's stock valued at $25,769,000 after purchasing an additional 28,967 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Ascendis Pharma A/S by 540.5% in the 4th quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company's stock valued at $76,000 after purchasing an additional 427 shares in the last quarter. New York State Common Retirement Fund boosted its stake in shares of Ascendis Pharma A/S by 14.0% in the 4th quarter. New York State Common Retirement Fund now owns 204,482 shares of the biotechnology company's stock valued at $28,151,000 after purchasing an additional 25,164 shares in the last quarter. Finally, Proficio Capital Partners LLC bought a new stake in Ascendis Pharma A/S during the 4th quarter valued at $1,725,000.

Ascendis Pharma A/S Price Performance

ASND stock traded up $0.06 during trading on Friday, hitting $157.60. 502,233 shares of the stock traded hands, compared to its average volume of 493,596. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $183.00. The firm's 50 day moving average is $157.15 and its two-hundred day moving average is $142.64. The stock has a market cap of $9.61 billion, a price-to-earnings ratio of -22.20 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The firm had revenue of $123.97 million for the quarter, compared to analysts' expectations of $98.56 million. As a group, analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on ASND. The Goldman Sachs Group upped their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Royal Bank of Canada upped their price target on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Morgan Stanley upgraded shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $180.00 to $250.00 in a report on Monday, May 5th. Cantor Fitzgerald restated an "overweight" rating and issued a $200.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, May 12th. Finally, Wedbush upped their price objective on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $216.07.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.